Indian pharmaceutical company Aurobindo Pharma $ARBN.SW has reported a 10% decrease in net profit for the third quarter, amounting to 8.46 billion rupees (approximately 96.6 million USD) for the period ending December 31. This decline is primarily attributed to a sharp increase in operating expenses, which have outstripped the revenue from generic drug sales.